drugset
drugset / Trial / NCT02254122

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

NCT02254122 ↗

Phase 1 Completed 59 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of BEA 2180 BR

Timeline

Start
2004-05
Primary completion
2005-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BEA 2180 BR Unknown 20 ug Other
Subject BEA 2180 BR Unknown 50 ug Other
Subject BEA 2180 BR Unknown 100 ug Other
Subject BEA 2180 BR Unknown 200 ug Other
Subject BEA 2180 BR Unknown 400 ug Other

Indications

No indication recorded.